NetworkNewsBreaks – ABcann Global Corporation (T
Post# of 111
(Total Views: 389)
Posted On: 06/30/2017 6:24:11 PM
NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Announces Appointment of Dr. Michael Shannon as Chief Medical Consultant
On Thursday, ABcann Global Corporation (TSXV: ABCN) announced that it has retained the services of Dr. Michael Shannon as its chief medical consultant. Shannon brings decades of health care experience to the ABcann team, including time in both the private and public sectors. Among Shannon’s career highlights, in 1996, he assumed responsibilities within Health Canada for re-organizing the Canadian blood system and the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. In 2000, he entered the private sector, simultaneously directing a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. “In the future we plan to participate in a number of clinical trials involving different modes of delivery as well as various research projects with potentially significant clinical implications in order to facilitate the acceptance of cannabis treatment by the mainstream medical community,” Aaron Keay, CEO of ABcann, noted in the news release. “Dr. Shannon’s experience and expertise, along with his established credibility, will help us through this process as we move these developments forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
On Thursday, ABcann Global Corporation (TSXV: ABCN) announced that it has retained the services of Dr. Michael Shannon as its chief medical consultant. Shannon brings decades of health care experience to the ABcann team, including time in both the private and public sectors. Among Shannon’s career highlights, in 1996, he assumed responsibilities within Health Canada for re-organizing the Canadian blood system and the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. In 2000, he entered the private sector, simultaneously directing a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. “In the future we plan to participate in a number of clinical trials involving different modes of delivery as well as various research projects with potentially significant clinical implications in order to facilitate the acceptance of cannabis treatment by the mainstream medical community,” Aaron Keay, CEO of ABcann, noted in the news release. “Dr. Shannon’s experience and expertise, along with his established credibility, will help us through this process as we move these developments forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)